Deslauriers, Frédérique
Gosselin-Boucher, Vincent
Léger, Camille
Vieira, Ariany Marques
Bacon, Simon L.
Lavoie, Kim L.
Funding for this research was provided by:
Canadian Institutes of Health Research (MM1-174903)
Fonds de Recherche du Québec - Santé (251618)
Fonds de Recherche du Québec-Société et Culture (2019-SE1-252541)
Ministère de l’économie et de l’innovation du Québec (2020-2022-COVID-19-PSOv2a-51754)
Article History
Received: 6 October 2022
Accepted: 11 April 2023
First Online: 26 October 2023
Declarations
:
: This study was approved by the Research Ethics Board of the Centre intégré universitaire de santé et de services sociaux du Nord-de-l’île-de-Montréal (CIUSSS-NIM), REB#: 2020–2099 / 25-03-2020. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants.
: Not applicable.
: KLL has served on the advisory board for Schering-Plough, Takeda, AbbVie, Almirall, Janssen, GSK, Boehringer Ingelheim (BI) and Sojecci Inc and has received sponsorship for investigator-generated research grants from GlaxoSmithKline (GSK) and AbbVie, speaker fees from GSK, Astra-Zeneca, Astellas, Novartis, Takeda, AbbVie, Merck, Boehringer Ingelheim, Bayer, Pfizer and Air Liquide, and support for educational materials from Merck, none of which are related to the current article. SB has received consultancy fees from Merck for the development of behavior change continuing education modules, speaker fees from Novartis and Janssen and has served on advisory boards for Bayer, Sanofi and Sojecci Inc, none of which are related to the current article. There are no other competing interests related to the authors of this manuscript.